Transient receptor potential melastatin 6 and transient receptor potential melastatin 6/7 antagonists suppress colon adenocarcinoma HT-29 cells

Figure 2 Mg²⁺ influx and total Mg content in cancer spheroids. A: Mg²⁺ influx in parental HT-29 cells compared with spheroid (SP)-derived HT-29 cells; B: Mg²⁺ influx in SP cells with or without the Mg²⁺ channel inhibitor Co(III)hexamine; C: Mg²⁺ influx in SP cells with or without the transient receptor potential melastatin 6/7 inhibitor 2-aminoethyl diphenylborinate; D: Mg²⁺ influx in SP cells with or without the transient receptor potential melastatin 6 inhibitor Mesendogen; E: Michaelis-Menten kinetic analysis of ΔF/F values between 40 and 160 seconds in parental HT-29 vs SP cells, SP vs SP with Co(III)hexamine, SP vs SP with 2-aminoethyl diphenylborinate, and SP vs SP with Mesendogen; F: Total intracellular Mg²⁺ content; G: Free intracellular Mg²⁺ level. SP: Spheroid; Co(III)hex: Co(III)hexamine; 2-APB: 2-aminoethyl diphenylborinate; ME: Mesendogen. ^aP < 0.05 vs parental HT-29 cells, ^bP < 0.01 vs parental HT-29 cells, ^cP < 0.001 vs parental HT-29 cells, ^dP < 0.05 vs spheroid group, ^eP < 0.01 vs spheroid group, and ^fP < 0.001 vs spheroid group.